文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA × BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data.

作者信息

Gottlieb Alice B, Merola Joseph F, Chen Rongdean, Levi Eugenia, Duffin Kristina Callis

机构信息

New York Medical College, Valhalla, New York.

Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

出版信息

J Am Acad Dermatol. 2017 Dec;77(6):1178-1180. doi: 10.1016/j.jaad.2017.06.162.

DOI:10.1016/j.jaad.2017.06.162
PMID:29132853
Abstract
摘要

相似文献

[1]
Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA × BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data.

J Am Acad Dermatol. 2017-12

[2]
Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2.

J Drugs Dermatol. 2017-2-1

[3]
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).

J Am Acad Dermatol. 2016-1

[4]
Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.

J Drugs Dermatol. 2017-12-1

[5]
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.

J Am Acad Dermatol. 2016-3-24

[6]
Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.

J Am Acad Dermatol. 2016-7-28

[7]
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.

J Drugs Dermatol. 2013-8

[8]
The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.

Adv Clin Exp Med. 2017-8

[9]
Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.

J Drugs Dermatol. 2016-3

[10]
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.

Acta Derm Venereol. 2016-5

引用本文的文献

[1]
Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry.

J Psoriasis Psoriatic Arthritis. 2023-4

[2]
Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice.

Exp Dermatol. 2024-8

[3]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2023-7-12

[4]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2022-5-23

[5]
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.

Dermatol Ther (Heidelb). 2022-2

[6]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2021-4-19

[7]
Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): A practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children.

J Am Acad Dermatol. 2020-1-21

[8]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2020-1-9

[9]
Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology.

An Bras Dermatol. 2019-4

[10]
Exploration of the Product of the 5-Point Investigator's Global Assessment and Body Surface Area (IGA × BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis.

Dermatology. 2019-5-29

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索